<i>N</i>‐acetylcysteine as a new prominent approach for treating psychiatric disorders

Smaga, Irena; Frankowska, Małgorzata; Filip, Małgorzata

doi:10.1111/bph.15456

Cited by 30 publications

(20 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In post-traumatic stress disorder (PTSD), people exhibit hypoactive executive functioning and hyperactive fear circuitry activity secondary to increased oxidative stress, inflammatory processes, and stress-related adaptations at glutamatergic synapses [ 129 , 130 ]. Glutathione is dysregulated in patients with PTSD [ 131 ].…”

Section: Post-traumatic Stress Disordermentioning

confidence: 99%

The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

N -acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders, schizophrenia spectrum disorders, bipolar-related disorders, depressive disorders, anxiety disorders, obsessive compulsive-related disorders, substance-use disorders, neurocognitive disorders, and chronic pain. Whilst there is ample preclinical evidence and theoretical justification for the use of NAC in the treatment of multiple psychiatric disorders, clinical trials in most disorders have yielded mixed results. However, most studies have been underpowered and perhaps too brief, with some evidence of benefit only after months of treatment with NAC. Currently NAC has the most evidence of having a beneficial effect as an adjuvant agent in the negative symptoms of schizophrenia, severe autism, depression, and obsessive compulsive and related disorders. Future research with well-powered studies that are of sufficient length will be critical to better understand the utility of NAC in the treatment of psychiatric disorders.

show abstract

Section: Post-traumatic Stress Disordermentioning

confidence: 99%

The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This restores the extracellular glutamate levels [ 15 ], which can be used for the synergistic treatment of obsessive–compulsive disorder. One study showed that NAC is a promising candidate for adjunct treatment for many psychiatric disorders, such as anxiety, bipolar disorder, depression, OCD, OCRD, posttraumatic stress disorder, and schizophrenia [ 16 ]. A randomized controlled trial using NAC as an adjuvant with the use of fluoxetine showed significant improvement in the NAC group in the treatment of moderate-to-severe OCD [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

A case of trichotillomania with binge eating disorder: combined with N-acetylcysteine synergistic therapy

et al. 2021

View full text Add to dashboard Cite

Background Obsessive–compulsive and related disorders (OCRDs) are a group of intractable and chronic mental disorders. Trichotillomania (TTM) is a common type of OCRDs characterized by repetitive hair pulling, driven by escalating tension before the action and during the attempts to resist it. Binge eating disorder (BED) is a common type of eating disorder characterized by recurrent compulsive episodes of binge eating. Both have common psychological processes (tension or impulsion) and pathological manifestations (out of control), but the pathological mechanisms are still unclear and the current clinical treatments are often unsatisfactory for these two disorders. Case presentation A 25-year-old woman with TTM comorbid BED came to our hospital for treatment. She had accepted systematic cognitive behavioral therapy (CBT) and also monotherapy or multidrug therapy with sertraline, fluvoxamine, bupropion, risperidone in full dosage and duration for 2 years, but all of them did not work. We treated this case with N-acetylcysteine (NAC) as a synergist on the basis of recent treatment (fluvoxamine 150 mg/day and bupropion 300 mg/day). The pathological hair plucking behavior and binge eating symptoms were both significantly and rapidly improved, and the follow-up in next 14 weeks showed that the effect was still maintained. Conclusion To our knowledge, this may be the first case report of using NAC as a synergist to treat TTM comorbid BED successfully, which suggest that these two disorders may have a common pathophysiological mechanism. Moreover, NAC can be one choice as a synergistic treatment for OCRDs.

show abstract

“…N-acetylcysteine (NAC), a precursor of antioxidant glutathione, exerts a wide range of protective effects, such as the regulation of oxidative status, inflammation, and monoamine neurotransmission in rodent models and human patients [137,138]. NAC showed a beneficial effect mainly on the negative symptoms of patients with schizophrenia receiving antipsychotic treatment (comprehensively reviewed in [139]). It is possible to achieve these therapeutic effects of NAC by multiple mechanisms, such as modulation of the oxidative and inflammation statuses, and neurotransmission.…”

Section: Perspective For Medication Drug Therapy In Schizophreniamentioning

confidence: 99%

Psychoneurobiology Research and Personalized Treatment of Schizophrenia

2022

View full text Add to dashboard Cite

show abstract

N‐acetylcysteine as a new prominent approach for treating psychiatric disorders

Cited by 30 publications

References 148 publications

The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

A case of trichotillomania with binge eating disorder: combined with N-acetylcysteine synergistic therapy

Psychoneurobiology Research and Personalized Treatment of Schizophrenia

Contact Info

Product

Resources

About